AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Abbvie (ABBV) PT Raised to $154 at BMO Capital
February 3, 2022 7:19 AM ESTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $154.00 (from $153.00) while maintaining an Outperform rating.
The analyst commented, "4Q good overall despite slight revenue shortfall as many key growth drivers performed well and better op. leverage drove EPS... More
AbbVie (ABBV) Tops Q4 EPS by 3c, Offers Guidance
February 2, 2022 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.31, $0.03 better than the analyst estimate of $3.28. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.95 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $14.00-$14.20, versus the consensus of... More
